We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
SRP14 is not prognostic in Glioblastoma Multiforme (TCGA)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
271.1
Number of samples
141
Samples
Sample
Description
TPM
TCGA-28-5220-01A
0 years, male, white, stage:'--, dead, 388 days
636.3
TCGA-06-5859-01A
0 years, male, white, stage:'--, alive, 139 days
546.3
TCGA-06-1804-01A
0 years, female, white, stage:'--, dead, 414 days
503.0
TCGA-14-1829-01A
0 years, male, black or african american, stage:'--, alive, 218 days
500.8
TCGA-06-2567-01A
0 years, male, white, stage:'--, dead, 133 days
487.4
TCGA-06-5411-01A
0 years, male, white, stage:'--, dead, 254 days
464.9
TCGA-14-2554-01A
0 years, female, white, stage:'--, dead, 532 days
455.9
TCGA-28-5207-01A
0 years, male, white, stage:'--, dead, 343 days
448.8
TCGA-28-2509-01A
0 years, female, white, stage:'--, alive, 145 days
444.0
TCGA-06-5408-01A
0 years, female, white, stage:'--, dead, 357 days
442.8
TCGA-06-0184-01A
0 years, male, white, stage:'--, dead, 2126 days
424.6
TCGA-32-5222-01A
0 years, male, white, stage:'--, dead, 585 days
384.2
TCGA-06-0219-01A
0 years, male, white, stage:'--, dead, 22 days
383.1
TCGA-19-2620-01A
0 years, male, white, stage:'--, dead, 148 days
379.4
TCGA-27-2526-01A
0 years, female, white, stage:'--, dead, 87 days
377.9
TCGA-28-5208-01A
0 years, male, white, stage:'--, dead, 544 days
376.3
TCGA-14-1823-01A
0 years, female, white, stage:'--, dead, 543 days
374.6
TCGA-28-5204-01A
0 years, male, white, stage:'--, dead, 454 days
373.0
TCGA-14-1034-01A
0 years, female, stage:'--, dead, 485 days
365.8
TCGA-12-5295-01A
0 years, female, white, stage:'--, dead, 454 days
362.2
TCGA-06-5856-01A
0 years, male, white, stage:'--, dead, 114 days
359.5
TCGA-27-1832-01A
0 years, female, white, stage:'--, dead, 300 days
353.7
TCGA-06-5410-01A
0 years, female, white, stage:'--, dead, 108 days
353.0
TCGA-06-0749-01A
0 years, male, black or african american, stage:'--, dead, 82 days
350.0
TCGA-76-4929-01A
0 years, female, white, stage:'--, dead, 111 days
348.0
TCGA-12-0616-01A
0 years, female, white, stage:'--, dead, 448 days
345.5
TCGA-06-0882-01A
0 years, male, white, stage:'--, dead, 632 days
344.4
TCGA-26-5139-01A
0 years, female, white, stage:'--, alive, 48 days
338.0
TCGA-32-1980-01A
0 years, male, white, stage:'--, dead, 36 days
335.3
TCGA-06-0750-01A
0 years, male, white, stage:'--, dead, 28 days
332.1
TCGA-06-5417-01A
0 years, female, white, stage:'--, alive, 155 days
331.2
TCGA-06-5858-01A
0 years, female, white, stage:'--, alive, 187 days
325.2
TCGA-06-0178-01A
0 years, male, white, stage:'--, dead, 2681 days
318.8
TCGA-15-1444-01A
0 years, male, white, stage:'--, dead, 1537 days
318.7
TCGA-06-5412-01A
0 years, female, white, stage:'--, dead, 138 days
316.4
TCGA-27-2521-01A
0 years, male, white, stage:'--, dead, 510 days
316.4
TCGA-02-0055-01A
0 years, female, white, stage:'--, dead, 76 days
313.5
TCGA-41-4097-01A
0 years, female, white, stage:'--, dead, 6 days
309.4
TCGA-28-5216-01A
0 years, male, white, stage:'--, alive, 415 days
308.2
TCGA-06-0130-01A
0 years, male, white, stage:'--, dead, 394 days
307.0
TCGA-02-2486-01A
0 years, male, white, stage:'--, dead, 618 days
306.8
TCGA-28-1753-01A
0 years, male, white, stage:'--, alive, 37 days
306.4
TCGA-26-5132-01A
0 years, male, white, stage:'--, alive, 286 days
305.0
TCGA-12-3652-01A
0 years, male, white, stage:'--, dead, 1062 days
301.7
TCGA-32-2615-01A
0 years, male, white, stage:'--, dead, 485 days
300.4
TCGA-02-2485-01A
0 years, male, black or african american, stage:'--, alive, 470 days
299.5
TCGA-19-2625-01A
0 years, female, white, stage:'--, dead, 124 days
296.3
TCGA-06-0138-01A
0 years, male, white, stage:'--, dead, 737 days
295.1
TCGA-32-2632-01A
0 years, male, white, stage:'--, dead, 269 days
295.0
TCGA-12-5299-01A
0 years, female, white, stage:'--, dead, 98 days
294.1
TCGA-28-5209-01A
0 years, female, white, stage:'--, alive, 442 days
293.5
TCGA-06-0168-01A
0 years, female, white, stage:'--, dead, 598 days
286.2
TCGA-15-0742-01A
0 years, male, white, stage:'--, dead, 419 days
285.5
TCGA-06-5413-01A
0 years, male, white, stage:'--, alive, 268 days
285.3
TCGA-06-0132-01A
0 years, male, white, stage:'--, dead, 771 days
285.2
TCGA-14-0787-01A
0 years, male, asian, stage:'--, dead, 68 days
282.2
TCGA-27-2528-01A
0 years, male, white, stage:'--, dead, 480 days
281.7
TCGA-32-1982-01A
0 years, female, white, stage:'--, dead, 142 days
280.8
TCGA-19-2624-01A
0 years, male, white, stage:'--, dead, 5 days
280.6
TCGA-76-4927-01A
0 years, male, white, stage:'--, dead, 535 days
280.3
TCGA-27-1831-01A
0 years, male, white, stage:'--, dead, 505 days
278.0
TCGA-06-2564-01A
0 years, male, white, stage:'--, alive, 181 days
277.4
TCGA-06-0747-01A
0 years, male, white, stage:'--, dead, 82 days
273.9
TCGA-06-2565-01A
0 years, male, asian, stage:'--, dead, 506 days
270.7
TCGA-06-0878-01A
0 years, male, white, stage:'--, alive, 218 days
270.5
TCGA-08-0386-01A
0 years, male, white, stage:'--, dead, 548 days
269.0
TCGA-14-0817-01A
0 years, female, white, stage:'--, dead, 164 days
268.8
TCGA-28-5218-01A
0 years, male, white, stage:'--, dead, 157 days
268.5
TCGA-06-0158-01A
0 years, male, white, stage:'--, dead, 329 days
266.0
TCGA-26-1442-01A
0 years, male, white, stage:'--, alive, 953 days
262.7
TCGA-06-2563-01A
0 years, female, white, stage:'--, alive, 932 days
258.6
TCGA-06-5414-01A
0 years, male, white, stage:'--, alive, 273 days
258.5
TCGA-12-3653-01A
0 years, female, white, stage:'--, dead, 442 days
257.0
TCGA-19-2619-01A
0 years, female, black or african american, stage:'--, alive, 294 days
256.6
TCGA-32-1970-01A
0 years, male, white, stage:'--, dead, 468 days
256.5
TCGA-06-0644-01A
0 years, male, black or african american, stage:'--, dead, 384 days
256.2
TCGA-02-2483-01A
0 years, male, asian, stage:'--, alive, 466 days
254.8
TCGA-06-2561-01A
0 years, female, white, stage:'--, dead, 537 days
253.2
TCGA-32-2634-01A
0 years, male, white, stage:'--, alive, 693 days
251.5
TCGA-76-4932-01A
0 years, female, white, stage:'--, dead, 1458 days
250.4
TCGA-06-0156-01A
0 years, male, white, stage:'--, dead, 178 days
247.9
TCGA-14-1825-01A
0 years, male, white, stage:'--, dead, 232 days
245.0
TCGA-06-2570-01A
0 years, female, white, stage:'--, alive, 958 days
243.9
TCGA-06-0139-01A
0 years, male, white, stage:'--, dead, 362 days
243.8
TCGA-28-5215-01A
0 years, female, white, stage:'--, dead, 335 days
243.5
TCGA-06-0744-01A
0 years, male, white, stage:'--, dead, 1426 days
239.7
TCGA-32-2638-01A
0 years, male, white, stage:'--, dead, 766 days
239.2
TCGA-76-4931-01A
0 years, female, white, stage:'--, dead, 279 days
239.1
TCGA-19-5960-01A
0 years, male, white, stage:'--, dead, 455 days
238.9
TCGA-27-2523-01A
0 years, male, white, stage:'--, dead, 489 days
232.5
TCGA-06-5418-01A
0 years, female, white, stage:'--, dead, 83 days
228.4
TCGA-06-0157-01A
0 years, female, white, stage:'--, dead, 97 days
228.0
TCGA-26-5133-01A
0 years, male, white, stage:'--, alive, 452 days
225.8
TCGA-06-0743-01A
0 years, male, white, stage:'--, dead, 803 days
220.1
TCGA-27-1835-01A
0 years, female, white, stage:'--, dead, 648 days
220.0
TCGA-06-0238-01A
0 years, male, white, stage:'--, dead, 405 days
219.4
TCGA-27-1837-01A
0 years, male, white, stage:'--, dead, 427 days
218.0
TCGA-06-2558-01A
0 years, female, white, stage:'--, dead, 380 days
216.4
TCGA-14-0789-01A
0 years, male, white, stage:'--, dead, 342 days
215.4
TCGA-06-2569-01A
0 years, female, black or african american, stage:'--, alive, 13 days
215.1
TCGA-06-0141-01A
0 years, male, white, stage:'--, dead, 313 days
214.7
TCGA-41-2572-01A
0 years, male, white, stage:'--, dead, 406 days
212.3
TCGA-06-0187-01A
0 years, male, white, stage:'--, dead, 828 days
209.8
TCGA-12-3650-01A
0 years, male, white, stage:'--, dead, 333 days
208.9
TCGA-06-0129-01A
0 years, male, asian, stage:'--, dead, 1024 days
207.0
TCGA-06-0645-01A
0 years, female, white, stage:'--, dead, 175 days
203.0
TCGA-06-0210-01A
0 years, female, white, stage:'--, dead, 225 days
202.5
TCGA-06-2557-01A
0 years, male, black or african american, stage:'--, dead, 33 days
201.6
TCGA-19-2629-01A
0 years, male, white, stage:'--, dead, 737 days
200.2
TCGA-06-2559-01A
0 years, male, white, stage:'--, dead, 150 days
198.3
TCGA-12-0821-01A
0 years, male, white, stage:'--, dead, 323 days
197.3
TCGA-41-3915-01A
0 years, male, white, stage:'--, dead, 360 days
195.2
TCGA-19-1390-01A
0 years, female, white, stage:'--, dead, 772 days
194.0
TCGA-27-2524-01A
0 years, male, white, stage:'--, dead, 231 days
192.5
TCGA-06-5416-01A
0 years, female, white, stage:'--, alive, 204 days
191.6
TCGA-02-0047-01A
0 years, male, white, stage:'--, dead, 448 days
190.8
TCGA-14-0871-01A
0 years, female, white, stage:'--, dead, 880 days
190.7
TCGA-06-0174-01A
0 years, male, white, stage:'--, dead, 98 days
187.5
TCGA-26-5135-01A
0 years, female, white, stage:'--, dead, 270 days
184.7
TCGA-16-0846-01A
0 years, male, white, stage:'--, dead, 119 days
180.2
TCGA-27-2519-01A
0 years, male, white, stage:'--, dead, 550 days
179.8
TCGA-06-0211-01A
0 years, male, white, stage:'--, dead, 360 days
171.8
TCGA-06-0125-01A
0 years, female, white, stage:'--, dead, 1448 days
169.4
TCGA-27-1834-01A
0 years, male, white, stage:'--, dead, 1233 days
169.1
TCGA-28-2514-01A
0 years, male, asian, stage:'--, alive, 160 days
168.8
TCGA-06-0646-01A
0 years, male, white, stage:'--, dead, 175 days
168.7
TCGA-06-0745-01A
0 years, male, white, stage:'--, dead, 239 days
159.0
TCGA-28-2513-01A
0 years, female, white, stage:'--, alive, 222 days
157.2
TCGA-76-4925-01A
0 years, male, white, stage:'--, dead, 146 days
156.8
TCGA-19-4065-01A
0 years, male, white, stage:'--, alive, 214 days
156.6
TCGA-27-1830-01A
0 years, male, white, stage:'--, dead, 154 days
156.1
TCGA-06-0686-01A
0 years, male, white, stage:'--, dead, 432 days
154.7
TCGA-41-5651-01A
0 years, female, black or african american, stage:'--, dead, 460 days
151.9
TCGA-32-2616-01A
0 years, female, white, stage:'--, dead, 224 days
150.3
TCGA-06-0190-01A
0 years, male, white, stage:'--, dead, 317 days
145.2
TCGA-12-0619-01A
0 years, male, white, stage:'--, dead, 1062 days
137.0
TCGA-32-4213-01A
0 years, female, white, stage:'--, alive, 604 days
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
SRP14 is not prognostic in Glioblastoma Multiforme (validation)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
44.9
Number of samples
58
Samples
Sample
Description
TPM
AK139
N, NA, stage:NA, dead, 270 days
69.7
AK041
N, NA, stage:NA, alive, 810 days
69.2
AK216
N, NA, stage:NA, dead, 360 days
67.1
AK030
N, NA, stage:NA, dead, 120 days
65.6
AK236
N, NA, stage:NA, dead, 360 days
64.9
AK035
N, NA, stage:NA, dead, 210 days
64.5
AK231
N, NA, stage:NA, dead, 240 days
63.4
AK066
N, NA, stage:NA, alive, 960 days
62.9
AK099
N, NA, stage:NA, dead, 420 days
57.9
AK134
N, NA, stage:NA, dead, 360 days
57.7
AK043
N, NA, stage:NA, alive, 660 days
56.8
AK068
N, NA, stage:NA, alive, 360 days
56.4
AK227
N, NA, stage:NA, alive, 300 days
54.6
AK100
N, NA, stage:NA, alive, 960 days
52.5
AK071
N, NA, stage:NA, dead, 540 days
52.2
AK005
N, NA, stage:NA, dead, 240 days
51.2
AK153
N, NA, stage:NA, dead, 240 days
50.7
AK117
N, NA, stage:NA, dead, 210 days
50.4
AK055
N, NA, stage:NA, dead, 240 days
49.9
AK158
N, NA, stage:NA, dead, 360 days
49.8
AK133
N, NA, stage:NA, dead, 360 days
48.8
AK199
N, NA, stage:NA, alive, 1860 days
48.4
AK213
N, NA, stage:NA, alive, 2010 days
47.6
AK218
N, NA, stage:NA, dead, 180 days
47.3
AK002
N, NA, stage:NA, dead, 570 days
47.0
AK098
N, NA, stage:NA, dead, 660 days
47.0
AK188
N, NA, stage:NA, alive, 420 days
46.6
AK173
N, NA, stage:NA, dead, 180 days
46.1
AK074
N, NA, stage:NA, alive, 300 days
44.7
AK167
N, NA, stage:NA, dead, 180 days
44.7
AK081
N, NA, stage:NA, dead, 180 days
44.1
AK088
N, NA, stage:NA, dead, 360 days
44.0
AK124
N, NA, stage:NA, alive, 1920 days
43.9
AK195
N, NA, stage:NA, dead, 390 days
43.5
AK226
N, NA, stage:NA, dead, 360 days
43.1
AK085
N, NA, stage:NA, alive, 660 days
41.5
AK015
N, NA, stage:NA, alive, 720 days
40.6
AK185
N, NA, stage:NA, alive, 330 days
40.0
AK178
N, NA, stage:NA, dead, 240 days
39.8
AK079
N, NA, stage:NA, dead, 210 days
38.9
AK076
N, NA, stage:NA, alive, 660 days
37.8
AK205
N, NA, stage:NA, dead, 120 days
37.4
AK089
N, NA, stage:NA, dead, 330 days
37.3
AK149
N, NA, stage:NA, dead, 420 days
36.6
AK183
N, NA, stage:NA, alive, 360 days
36.0
AK051
N, NA, stage:NA, dead, 360 days
34.9
AK142
N, NA, stage:NA, alive, 90 days
34.9
AK072
N, NA, stage:NA, dead, 150 days
33.7
AK003
N, NA, stage:NA, dead, 600 days
32.3
AK103
N, NA, stage:NA, alive, 1320 days
30.5
AK156
N, NA, stage:NA, dead, 330 days
30.5
AK123
N, NA, stage:NA, dead, 180 days
29.9
AK102
N, NA, stage:NA, alive, 1740 days
27.5
AK006
N, NA, stage:NA, dead, 360 days
26.7
AK091
N, NA, stage:NA, dead, 210 days
26.7
AK053
N, NA, stage:NA, dead, 300 days
23.5
AK165
N, NA, stage:NA, alive, 360 days
20.3
AK049
N, NA, stage:NA, dead, 180 days
18.5
Show allShow less
GLIOBLASTOMA MULTIFORME - Protein relative expression (CPTAC)
Number of samples
110
Samples
Sample ID
Sample type
nRPX
CPT0078580003
Tumor
1.1
CPT0217190003
Tumor
0.9
CPT0168080003
Tumor
0.7
CPT0162140003
Tumor
0.6
CPT0218770003
Tumor
0.6
CPT0206780003
Tumor
0.5
CPT0201710003
Tumor
0.5
CPT0217710008
Tumor
0.5
CPT0161730003
Tumor
0.5
CPT0189570004
Tumor
0.5
CPT0208980003
Tumor
0.5
CPT0087680003
Tumor
0.4
CPT0206670004
Tumor
0.4
CPT0206560003
Tumor
0.4
CPT0093450003
Tumor
0.4
CPT0190240004
Tumor
0.4
CPT0218830004
Tumor
0.4
CPT0207090003
Tumor
0.4
CPT0127480003
Tumor
0.4
CPT0217430008
Tumor
0.3
CPT0206230003
Tumor
0.3
CPT0217100003
Tumor
0.3
CPT0182500003
Tumor
0.3
CPT0218330004
Tumor
0.3
CPT0224390004
Tumor
0.3
CPT0167530003
Tumor
0.3
CPT0217000004
Tumor
0.3
CPT0218690004
Tumor
0.3
CPT0205780003
Tumor
0.2
CPT0071100003
Tumor
0.2
CPT0218890004
Tumor
0.2
CPT0182550003
Tumor
0.2
CPT0218670003
Tumor
0.2
CPT0167640003
Tumor
0.2
CPT0189750004
Tumor
0.2
CPT0167750004
Tumor
0.2
CPT0125570003
Tumor
0.2
CPT0225730003
Tumor
0.1
CPT0171580008
Tumor
0.1
CPT0206000004
Tumor
0.1
CPT0168270003
Tumor
0.1
CPT0182580003
Tumor
0.1
CPT0125220003
Tumor
0.1
CPT0167970003
Tumor
0.1
CPT0219080004
Tumor
0.1
CPT0205570003
Tumor
0.1
CPT0221180003
Tumor
0.1
CPT0224540004
Tumor
0.1
CPT0218960004
Tumor
0.0
CPT0168830003
Tumor
0.0
CPT0189460003
Tumor
0.0
CPT0224600003
Tumor
0.0
CPT0064890003
Tumor
0.0
CPT0189250003
Tumor
0.0
CPT0127420003
Tumor
0.0
CPT0205670004
Tumor
0.0
CPT0224330003
Tumor
0.0
CPT0125510003
Tumor
0.0
CPT0104330003
Tumor
0.0
CPT0216920008
Tumor
0.0
CPT0162100003
Tumor
0.0
CPT0175060003
Tumor
0.0
CPT0002410011
Tumor
-0.1
CPT0093510003
Tumor
-0.1
CPT0205890003
Tumor
-0.1
CPT0123530003
Tumor
-0.1
CPT0204330003
Normal
-0.1
CPT0225760003
Tumor
-0.1
CPT0217880003
Tumor
-0.1
CPT0189850004
Tumor
-0.1
CPT0092440003
Tumor
-0.1
CPT0217060003
Tumor
-0.1
CPT0207030003
Tumor
-0.1
CPT0087570003
Tumor
-0.1
CPT0168480003
Tumor
-0.1
CPT0205450004
Tumor
-0.2
CPT0190360004
Tumor
-0.2
CPT0168380003
Tumor
-0.2
CPT0204370003
Normal
-0.2
CPT0228220003
Tumor
-0.2
CPT0209440003
Tumor
-0.2
CPT0204380003
Normal
-0.2
CPT0093360003
Tumor
-0.2
CPT0093550003
Tumor
-0.2
CPT0204390003
Normal
-0.2
CPT0064650003
Tumor
-0.3
CPT0204420003
Normal
-0.3
CPT0199770003
Tumor
-0.3
CPT0206110003
Tumor
-0.3
CPT0186100003
Tumor
-0.3
CPT0089150003
Tumor
-0.3
CPT0168720003
Tumor
-0.3
CPT0204400003
Normal
-0.3
CPT0168590003
Tumor
-0.3
CPT0079790003
Tumor
-0.4
CPT0204350003
Normal
-0.4
CPT0206330003
Tumor
-0.4
CPT0206880003
Tumor
-0.4
CPT0206450003
Tumor
-0.4
CPT0104220003
Tumor
-0.4
CPT0162020003
Tumor
-0.4
CPT0087950003
Tumor
-0.4
CPT0204340003
Normal
-0.4
CPT0093590003
Tumor
-0.4
CPT0204410003
Normal
-0.4
CPT0196850003
Tumor
-0.5
CPT0167860004
Tumor
-0.5
CPT0204360003
Normal
-0.5
CPT0087730003
Tumor
-0.5
CPT0189650004
Tumor
-0.8
Show allShow less
GLIOMA - Protein expressioni
A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.
Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.